Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
MedTech segment becoming the primary value driver as surgical robotics and cardiovascular tech scale.
Draconian talc settlement exceeding $25B and affecting long-term capital allocation.
Johnson & Johnson (JNJ) is a global healthcare titan operating in two dominant segments: Innovative Medicine and MedTech. Following the 2023 spin-off of its consumer health business (Kenvue), JNJ has transformed into a high-margin, innovation-led powerhouse. The company holds a 'Wide Moat' rating, driven by its massive pharmaceutical patent portfolio and its deeply integrated medical device platforms which benefit from high surgeon switching costs. As a 'Mature Quality Compounder,' JNJ's investment thesis rests on its ability to generate consistent, high-return cash flows across economic cycles. With a $14.7B R&D budget and a fortress balance sheet (Net Debt/EBITDA < 1.0x), JNJ is well-positioned to navigate the upcoming Stelara patent cliff and integrate recent high-growth acquisitions in the cardiovascular space. The current valuation is depressed by a significant 'litigation discount' related to multi-year talc lawsuits. We view the current 17.8x forward P/E as an undervaluation of a business with 21% ROIC and over 60 years of consecutive dividend growth.
Johnson & Johnson (JNJ) is a global healthcare titan operating in two dominant segments: Innovative Medicine and MedTech. Following the 2023 spin-off of its consumer health business (Kenvue), JNJ has transformed into a high-margin, innovation-led powerhouse. The company holds a 'Wide Moat' rating, driven by its massive pharmaceutical patent portfolio and its deeply integrated medical device platforms which benefit from high surgeon switching costs. As a 'Mature Quality Compounder,' JNJ's investment thesis rests on its ability to generate consistent, high-return cash flows across economic cycles. With a $14.7B R&D budget and a fortress balance sheet (Net Debt/EBITDA < 1.0x), JNJ is well-positioned to navigate the upcoming Stelara patent cliff and integrate recent high-growth acquisitions in the cardiovascular space. The current valuation is depressed by a significant 'litigation discount' related to multi-year talc lawsuits. We view the current 17.8x forward P/E as an undervaluation of a business with 21% ROIC and over 60 years of consecutive dividend growth.
Fortress balance sheet capable of absorbing multi-billion dollar legal settlements.
Dividend King status with a safe 2.4% yield and high cash flow visibility.
Johnson & Johnson is a high-conviction defensive buy, offering a rare combination of quality, yield, and a clear path to value realization as legal uncertainties are resolved.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
The bear case centers on litigation becoming a permanent drain on capital rather than a one-time charge. If JNJ is forced into a fragmented litigation path with high jury awards, the 'headline risk' will cause persistent multiple compression below 15x forward earnings. This would be compounded if the Innovative Medicine pipeline fails to replace the revenue from Stelara as it goes off-patent. Furthermore, if the recent $13B+ MedTech acquisitions fail to integrate or achieve projected synergies, the ROIC would decline toward the WACC, eroding the 'Quality' premium the market currently assigns to the stock. In this scenario, JNJ becomes a 'value trap' with stagnant growth and legal overhangs.
Market exclusivity for Darzalex, Erleada, and Tremfya drives segment margins above 30%.
Extensive surgeon training on proprietary surgical and robotic platforms.
R&D budget of $14.7B allows for innovation cycle that smaller peers cannot match.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
N/A — JNJ is not a high-capex archetype and is consistently FCF positive.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Aggressive M&A activity (Shockwave, Abiomed) and increased R&D reinvestment rates across the sector. Increased competition for premium assets but also higher potential for breakthrough growth.
The healthcare sector is currently in an expansionary phase driven by aging global demographics and a recovery in elective surgical volumes post-pandemic. High-margin biologic innovation and the integration of AI in robotic surgery are providing fresh tailwinds for diversified giants.
The industry faces headwinds from the Inflation Reduction Act (IRA) drug pricing reforms and an intensifying patent cliff for major blockbusters. Litigation regarding legacy products remains a significant drag on sector multiples, particularly for diversified conglomerates.
Use normal position sizing discipline for the rating and risk profile.
Reassess or exit if the core thesis breaks.
The 'headline discount' due to talc litigation has created an attractive entry point for a Wide Moat asset trading below its intrinsic value.
While MedTech is accelerating, the overall EPS growth of 6% may be too slow for high-growth mandates until litigation is resolved.
A Dividend King with a 2.4% yield and a fortress balance sheet. JNJ is the ultimate 'sleep well at night' (SWAN) stock.
Johnson & Johnson represents a premier defensive healthcare play, combining a Wide-Moat Innovative Medicine segment with a high-growth MedTech portfolio. While litigation overhangs (talc) persist, the underlying business quality—characterized by an ROIC consistently 15pp above WACC—justifies a premium valuation. The market is currently pricing in a draconian litigation outcome, creating an attractive entry point for long-term compounders. Our analysis points to a fair value of $245.55, implying roughly 9% upside from current levels. When combined with a secure and growing dividend, the total return profile is highly attractive for risk-adjusted portfolios.
Upside case: A Dividend King with a 2.4% yield and a fortress balance sheet. JNJ is the ultimate 'sleep well at night' (SWAN) stock. Downside case: The 'headline discount' due to talc litigation has created an attractive entry point for a Wide Moat asset trading below its intrinsic value. Horizon: 3-5 Years.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Protracted legal battles and a failed R&D cycle lead to zero growth and multiple compression. The market treats JNJ as a 'distressed' defensive play rather than a growth compounder.
Talc settlement exceeding $25B or failure of the 'Texas Two-Step' strategy.
Revenue decline >15% without offset from new pipeline launches.
The five developments that would weaken our investment case.
Escalating legal settlement liabilities drain operating cash flow and divert balance sheet capacity away from pipeline acquisitions, constraining capital reallocation into high-growth pharmaceutical and medical technology programs.
Current:$11B (est) as of the 2026-04-28 analysis date
Alert ifTalc settlement exceeding $25B or failure of the 'Texas Two-Step' strategy
Decelerating medical device expansion reflects competitive market share losses in robotic and surgical platforms, dampening top-line diversification and undermining segment margin contribution across global hospital markets.
Current:6-7% as of the 2026-04-28 analysis date
Alert ifDecelerates below 3.0% YoY for two consecutive quarters
Structural compression in capital efficiency indicates that large medical technology acquisitions and pharmaceutical research expenditures are failing to generate returns above the corporate hurdle rate, destroying intrinsic business value.
Current:21.2% as of the 2026-04-28 analysis date
Alert ifDeclines below 12.0% for two consecutive fiscal years
Severe gross margin compression reflects biosimilar erosion against key pharmaceutical blockbusters combined with unfavorable product mix shift, reducing operating cash flow generation available for reinvestment and shareholder returns.
Current:67.9% for the period ended 2025-12-31
Alert ifCompresses below 64.0% for two consecutive fiscal quarters
A steep top-line contraction from patent exclusivity losses without compensating revenue from commercial immunology and oncology pipeline rollouts undermines operating scale and forces painful cuts to growth investments.
Current:6.0% for the period ended 2025-12-31
Alert ifRevenue decline >15% without offset from new pipeline launches
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at , then adjust for signed per current share.
Solve for the growth rate that makes the model value equal the report-date share price.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
In the bull case, JNJ resolves its talc liabilities for less than $10B, causing an immediate re-rating of the P/E multiple toward historical highs of 22-24x. MedTech organic growth accelerates as the cardiovascular acquisitions begin to cross-sell into the existing hospital network.
The business continues its steady compounding path. Litigation is settled within the range of $10-15B over a decade, which is easily funded by operational cash flow. The stock trades at a fair 18-20x multiple.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Warning level: Talc settlement exceeding $25B or failure of the 'Texas Two-Step' strategy. Escalating legal settlement liabilities drain operating cash flow and divert balance sheet capacity away from pipeline acquisitions, constraining capital reallocation into high-growth pharmaceutical and medical technology programs.
Warning level: Decelerates below 3.0% YoY for two consecutive quarters. Decelerating medical device expansion reflects competitive market share losses in robotic and surgical platforms, dampening top-line diversification and undermining segment margin contribution across global hospital markets.
Warning level: Declines below 12.0% for two consecutive fiscal years. Structural compression in capital efficiency indicates that large medical technology acquisitions and pharmaceutical research expenditures are failing to generate returns above the corporate hurdle rate, destroying intrinsic business value.
Warning level: Compresses below 64.0% for two consecutive fiscal quarters. Severe gross margin compression reflects biosimilar erosion against key pharmaceutical blockbusters combined with unfavorable product mix shift, reducing operating cash flow generation available for reinvestment and shareholder returns.
Warning level: Revenue decline >15% without offset from new pipeline launches. A steep top-line contraction from patent exclusivity losses without compensating revenue from commercial immunology and oncology pipeline rollouts undermines operating scale and forces painful cuts to growth investments.
| $85.16B |
| $88.82B |
| $94.19B |
| +5.6% |
| Gross profit | $55.39B | $58.61B | $61.35B | $63.94B | +4.9% |
| Operating income | $19.64B | $15.83B | $17.44B | $33.55B | +19.6% |
| Net income | $17.94B | $35.15B | $14.07B | $26.80B | +14.3% |
| EPS (diluted) | $6.73 | $13.72 | $5.79 | $11.03 | +17.9% |
| EBITDA | $26.61B | $23.32B | $24.78B | $41.06B | +15.6% |
| R&D | $14.14B | $15.09B | $17.23B | $14.67B | +1.2% |
| SG&A | $20.25B | $21.51B | $22.87B | $23.68B | +5.4% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 94,193,000,000 |
|---|---|
| Cost of revenue | 30,256,000,000 |
| Gross profit | 63,937,000,000 |
| Operating expenses | 38,341,000,000 |
| Operating income | 25,596,000,000 |
| Non-operating items and tax | 1,208,000,000 |
| Net income | 26,804,000,000 |
| Total assets | 199,210,000,000 |
|---|---|
| Cash | 19,709,000,000 |
| Current assets | 55,624,000,000 |
| Total liabilities | 117,666,000,000 |
| Current liabilities | 54,126,000,000 |
| Shareholders’ equity | 81,544,000,000 |
Point-in-time financial data used in the 2026-04-28 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 80B | 26.6B | 17.9B | 21.2B | 17.2B | 4B | 7B | 1.1B | 6B | 11.7B | 7.5B | — | — | — | — | 12.9B | 39.6B | 26.3% | — | — | — |
| 2023-12-31 | 85.2B | 23.3B | 35.2B | 22.8B | 17.8B | 5B | 7.5B | 1.2B | 5.1B | 11.8B | -2.7B | — | — | — | — | 21.9B | 29.3B | 25.8% | — | 6.3% | — |
| 2024-12-31 | 88.8B | 24.8B | 14.1B | 24.3B | 18.1B | 6.2B | 7.3B | 1.2B | 2.4B | 11.8B | 10.1B | — | — | — | — | 24.1B | 36.6B | 23.9% | — | 6.7% | — |
| 2025-12-31 | 94.2B | 41.1B | 26.8B | 24.5B | 19.3B | 5.2B | 7.5B | 1.4B | 6B | 12.4B | 9.6B | — | — | — | — | 19.7B | 47.9B | 27.2% | — | 6.4% | — |
JNJ trades at 17.9x forward earnings against a peer median of 13.3x; EV/EBITDA of 16.8x against a peer median of 13.8x; 6 peers.
| Global Aging | positive | Rising demand for chronic disease management and joint replacements. |
| Digital/Robotic Surgery | positive | Integration of data and precision tools improving surgical outcomes and margins. |
JNJ is uniquely positioned as the dominant diversified player. Unlike pure-play pharma, its MedTech arm provides a hedge against drug pricing legislation, while its Innovative Medicine segment provides higher margins than pure-play medical device companies.
| Level | Action |
|---|
| Thesis break | Reassess or exit if the core thesis breaks. |
This edition does not contain enough finite inputs to reproduce the lens calculation.
This edition does not contain enough finite inputs to reproduce the lens calculation.
| AbbVie Inc. |
| 12.3x |
| 5.7x |
| 14.2x |
| 62.2% |
| 34.1% |
| MRK | Merck & Co. Inc. | 11.3x | 4.2x | 10.6x | 36.9% | 32.8% |
| AMGN | Amgen Inc. | 14.6x | 5.0x | 13.8x | 106.1% | 30.5% |
| GILD | Gilead Sciences Inc. | 13.3x | 5.4x | 12.0x | 40.7% | 37.4% |
